Skip to content
lifestyle.forkstofeet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Corbus Pharmaceuticals Holdings, Inc.
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
August 6, 2026
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
August 4, 2026
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
July 28, 2026
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
July 6, 2026
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
May 26, 2026
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
May 5, 2026
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
April 22, 2026
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
April 14, 2026
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
April 7, 2026
1
2
Next Page
→